Cycle Time Metrics for Multisite Clinical Trials in the United States

Therapeutic Innovation and Regulatory Science

Volumn 47, Issue 2, 2013, Pages 152-160

  Abbott, Diana ^a   Califf, Robert ^a   Morrison, Briggs W ^b   Pierre, Christine ^c   Bolte, Jean ^a   Chakraborty, Swati ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c RxTrials Inc   (United States)

Author keywords

metrics; study start up; trials

Indexed keywords

ARTICLE; BIOTECHNOLOGY; DEMOGRAPHY; INFORMED CONSENT; MEDICAL RESEARCH; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RESEARCH SUBJECT; STANDARD; STATISTICAL ANALYSIS; TIME; UNITED STATES;

EID: 84877589607     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. The James Lind Library. Editorial commentary: fair tests of treatments in health care. Available at: www.jameslindlibrary.org. Accessed February 29, 2012.
2. Dilts D,Cheng SK.The importance of doing trials right while doing the right trials.Clin Cancer Res. 2012;18 (1): 3-5.
3. Sung NS,Crowley WF,Genel M, et al.Central challenges facing the national clinical research enterprise.JAMA. 2003;289 (10): 1278-1287.
4. Glickman SW,McHutchison JG,Peterson ED, et al.Ethical and scientific implications of the globalization of clinical research.N Engl J Med. 2009;360 (8): 816-823.
5. Kim ES,Carrigan TP,Menon V.International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute.J Am Coll Cardiol. 2011;58 (7): 671-676.
6. Califf RM,Harrington RA.American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy?.J Am Coll Cardiol. 2011;58 (7): 677-680.
7. Califf RM,Zarin DA,Kramer JM,Sherman RE,Aberle LH,Tasneem A.Characteristics of clinical trials registered in Clinical Trials.gov, 2007-2010.JAMA. 2012;307 (17): 1838-1847.
8. Abbott L,Grady C.A systematic review of the empirical literature evaluating IRBs: what we know and what we still need to learn.J Empir Res Hum Res Ethics. 2011;6 (1): 3-19.
9. Kruskal WH,Wallis WA.Use of ranks in one-criterion variance analysis.J Am Stat Assoc. 1952;47 (260): 583-621.
10. Lee DH,Vielemeyer O.Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines.Ann Intern Med. 2011;171:18-22.
11. Tricoci P,Allen JM,Kramer JM,Califf RM,Smith SC.Scientific evidence underlying the ACC/AHA clinical practice guidelines.JAMA. 2009;301 (8): 831-841.
12. DeMets D,Califf R.Lessons learned from recent cardiovascular clinical trials: part I.Circulation. 2002;106:746-751.
13. Bueno M,Brevidelli MM,Cocarelli T,Santos GM,Ferraz MA,Mion D.Reasons for resubmission of research projects to the research ethics committee of a university hospital in São Paulo, Brazil.Clinics (Sao Paulo). 2009;64 (9): 831-836.
14. De Feo G,Signoriello S,Bryce JC, et al.Time spent for activation of non-profit studies in oncology in Italy.PLoS One. 2010;5 (7): e11864.
15. Dilts DM,Sandler AB.Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.J Clin Oncol. 2006;24 (28): 4545-4552.
16. Dilts DM,Sandler AB,Baker M, et al.Processes to activate phase III clinical trials in a cooperative oncology group: the case of cancer and leukemia group B.J Clin Oncol. 2006;24 (28): 4553-4557.
17. DiltsDM, Sandler A,Cheng S, et al.Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group.Clin Cancer Res. 2008;14 (11): 3427-3433.
18. Dilts DM,Sandler AB,Cheng SK, et al.Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.J Clin Oncol. 2009;27 (11): 1761-1766.
19. Dilts DM,Cheng SK,Crites JS,Sandler AB,Doroshow JH.Phase III clinical trial development: a process of chutes and ladders.Clin Cancer Res. 2010;16 (22): 5381-5389.
20. Jester PM,Tilden SJ,Li Y,Whitley RJ,Sullender WM.Regulatory challenges: lessons from recent West Nile virus trials in the United States.Contemp Clin Trials. 2006;27 (3): 254-259.
21. Wang-Gillam A,Williams K,Novello S,Gao F,Scagliotti GV,Govindan R.Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the Atlantic.J Clin Oncol. 2010;28 (24): 3803-3807.
22. Burman W,Breese P,Weis S,Bock N,Bernardo J,Vernon A.The effects of local review on informed consent documents from a multicenter clinical trials consortium.Control Clin Trials. 2003;24 (3): 245-255.
23. Dziak K,Anderson R,Sevick MA,Weisman CS,Levine DW,Scholle SH.Variations among Institutional Review Board reviews in a multisite health services research study.Health Serv Res. 2005;40 (1): 279-290.
24. Finch SA,Barkin SL,Wasserman RC,Dhepyasuwan N,Slora EJ,Sege RD.Effects of local institutional review board review on participation in national practice-based research network studies.Arch Pediatr Adolesc Med. 2009;163 (12): 1130-1134.
25. Gold JL,Dewa CS.Institutional review boards and multisite studies in health services research: is there a better way?.Health Serv Res. 2005;40 (1): 291-307.
26. Green LA,Lowery JC,Kowalski CP,Wyszewianski L.Impact of institutional review board practice variation on observational health services research.Health Serv Res. 2006;41 (1): 214-230.
27. Greene SM,Geiger AM.A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval.J Clin Epidemiol. 2006;59 (8): 784-790.
28. Mansbach J,Acholonu U,Clark S,Camargo CA.Variation in institutional review board responses to a standard, observational, pediatric research protocol.Acad Emerg Med. 2007;14 (4): 377-380.
29. Newgard CD,Hui SH,Stamps-White P,Lewis RJ.Institutional variability in a minimal risk, population-based study: recognizing policy barriers to health services research.Health Serv Res. 2005;40 (4): 1247-1258.
30. Stair TO,Reed CR,Radeos MS,Koski G,Camargo CA.Variation in institutional review board responses to a standard protocol for a multicenter clinical trial.Acad Emerg Med. 2001;8 (6): 636-641.
31. Stark AR,Tyson JE,Hibberd PL.Variation among institutional review boards in evaluating the design of a multicenter randomized trial.J Perinatol. 2010;30 (3): 163-169.